» Articles » PMID: 33810420

Loading of Beclomethasone in Liposomes and Hyalurosomes Improved with Mucin As Effective Approach to Counteract the Oxidative Stress Generated by Cigarette Smoke Extract

Overview
Date 2021 Apr 3
PMID 33810420
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

In this work beclomethasone dipropionate was loaded into liposomes and hyalurosomes modified with mucin to improve the ability of the payload to counteract the oxidative stress and involved damages caused by cigarette smoke in the airway. The vesicles were prepared by dispersing all components in the appropriate vehicle and sonicating them, thus avoiding the use of organic solvents. Unilamellar and bilamellar vesicles small in size (~117 nm), homogeneously dispersed (polydispersity index lower than 0.22) and negatively charged (~-11 mV), were obtained. Moreover, these vesicle dispersions were stable for five months at room temperature (~25 °C). In vitro studies performed using the Next Generation Impactor confirmed the suitability of the formulations to be nebulized as they were capable of reaching the last stages of the impactor that mimic the deeper airways, thus improving the deposition of beclomethasone in the target site. Further, biocompatibility studies performed by using 16HBE bronchial epithelial cells confirmed the high biocompatibility and safety of all the vesicles. Among the tested formulations, only mucin-hyalurosomes were capable of effectively counteracting the production of reactive oxygen species (ROS) induced by cigarette smoke extract, suggesting that this formulation may represent a promising tool to reduce the damaging effects of cigarette smoke in the lung tissues, thus reducing the pathogenesis of cigarette smoke-associated diseases such as chronic obstructive pulmonary disease, emphysema, and cancer.

Citing Articles

Oxidative Stress and Antioxidants in Pediatric Asthma's Evolution and Management.

Ioniuc I, Lupu A, Dragan F, Tarnita I, Alexoae M, Streanga V Antioxidants (Basel). 2024; 13(11).

PMID: 39594473 PMC: 11590961. DOI: 10.3390/antiox13111331.


Characterization techniques for tobacco and its derivatives: a systematic review.

Shen K, Xia L, Jiao K, Pan F, Xiang B, Zhou W Front Chem. 2024; 12:1402502.

PMID: 39036657 PMC: 11257895. DOI: 10.3389/fchem.2024.1402502.


Liposomes as Carriers of GHK-Cu Tripeptide for Cosmetic Application.

Dymek M, Olechowska K, Hac-Wydro K, Sikora E Pharmaceutics. 2023; 15(10).

PMID: 37896245 PMC: 10610410. DOI: 10.3390/pharmaceutics15102485.


Oxidative Stress, Environmental Pollution, and Lifestyle as Determinants of Asthma in Children.

Di Vincenzo S, Ferrante G, Ferraro M, Cascio C, Malizia V, Licari A Biology (Basel). 2023; 12(1).

PMID: 36671825 PMC: 9856068. DOI: 10.3390/biology12010133.


Inhalable Mannosylated Rifampicin-Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy.

Galdoporpora J, Martinena C, Bernabeu E, Riedel J, Palmas L, Castangia I Pharmaceutics. 2022; 14(5).

PMID: 35631546 PMC: 9145552. DOI: 10.3390/pharmaceutics14050959.


References
1.
Rubin B . Air and soul: the science and application of aerosol therapy. Respir Care. 2010; 55(7):911-21. View

2.
Manca M, Castangia I, Caddeo C, Pando D, Escribano E, Valenti D . Improvement of quercetin protective effect against oxidative stress skin damages by incorporation in nanovesicles. Colloids Surf B Biointerfaces. 2014; 123:566-74. DOI: 10.1016/j.colsurfb.2014.09.059. View

3.
Lackie P, Baker J, Gunthert U, Holgate S . Expression of CD44 isoforms is increased in the airway epithelium of asthmatic subjects. Am J Respir Cell Mol Biol. 1997; 16(1):14-22. DOI: 10.1165/ajrcmb.16.1.8998074. View

4.
Pace E, Ferraro M, Di Vincenzo S, Gerbino S, Bruno A, Lanata L . Oxidative stress and innate immunity responses in cigarette smoke stimulated nasal epithelial cells. Toxicol In Vitro. 2013; 28(2):292-9. DOI: 10.1016/j.tiv.2013.11.004. View

5.
Lemarchand C, Gref R, Couvreur P . Polysaccharide-decorated nanoparticles. Eur J Pharm Biopharm. 2004; 58(2):327-41. DOI: 10.1016/j.ejpb.2004.02.016. View